Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(22)00837-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case with systemic juvenile idiopathic arthritis treated with tofacitinib and rapamycin.
Rheumatology (Oxford)
November 2024
Department of Pediatrics, Division of Rheumatology, Hacettepe University, Ankara, Turkey.
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction.
Arthritis Care Res (Hoboken)
November 2024
Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Objective: To assess changes in gene expression following tofacitinib treatment and investigate transcription patterns as potential predictors of treatment response in patients with active juvenile idiopathic arthritis (JIA).
Methods: Whole-blood samples were collected from patients with JIA at baseline and after 18 weeks of open-label tofacitinib treatment. Patients who achieved a JIA-American College of Rheumatology (ACR) response of 70% or above at week 18 were classified as treatment responders (TRs), whereas those with at most a JIA-ACR30 were classified as poor responders (PRs).
The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease (SJIA-LD): French experience.
Rheumatology (Oxford)
October 2024
Department of Pediatrics, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Objectives: A new form of systemic juvenile idiopathic arthritis (SJIA) with associated lung disease (SJIA-LD) has recently been described. Multiple lines of treatment have failed to yield satisfactory results for this disorder. JAK inhibitors (JAKis) have recently been approved for the treatment of JIA, but clinical evidence of their efficacy in SJIA-LD is still weak.
View Article and Find Full Text PDFTrends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022.
Arthritis Rheumatol
October 2024
Rutgers University, New Brunswick, New Jersey.
Objective: The objective of this study is to describe recent trends in disease-modifying antirheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States.
Methods: We used commercial claims data (2000-2022) to perform a serial cross-sectional utilization study of children aged 1 to 18 that were diagnosed with JIA. Initiations of conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs) were identified after a ≥12-month baseline and expressed as a percentage of all new DMARD initiations per year, by category, class, and individual agent.
14-month-old female with anti-MDA5 juvenile dermatomyositis complicated by liver disease: a case report.
Pediatr Rheumatol Online J
September 2024
Division of Rheumatology, Children's Mercy Hospital, Kansas City, MO, USA.
Article Synopsis
- Juvenile Dermatomyositis (JDM) is a rare autoimmune disorder with various subtypes, and anti-MDA5 is one of the associated myositis-specific antibodies, though treatment protocols are not well defined.
- A case study details a previously healthy 14-month-old girl with anti-MDA5 JDM presenting symptoms like rash, weakness, and liver issues, ultimately responding well to treatment with steroids and tofacitinib.
- This case highlights the importance of considering anti-MDA5 JDM when diagnosing patients with liver, muscle, and skin symptoms, emphasizing the need for standardized treatment approaches and more research into the mechanisms of the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!